Mankind Pharma Limited (NSE: MANKIND)

Mankind Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	110,180	103,348	87,494	77,816	62,144	58,719
Revenue Growth (YoY)	16.84%	18.12%	12.44%	25.22%	5.83%	17.91%
Cost of Revenue	33,633	33,207	30,031	24,879	18,471	19,219
Gross Profit	76,547	70,141	57,463	52,937	43,673	39,500
Selling, General & Admin	30,572	29,018	23,126	20,934	18,195	16,082
Other Operating Expenses	17,678	15,622	15,195	12,014	8,386	7,722
Operating Expenses	52,527	48,622	41,580	34,614	27,770	24,794
Operating Income	24,020	21,518	15,883	18,322	15,903	14,706
Interest Expense	-316.5	-286	-402.74	-557.8	-193.03	-215.51
Interest & Investment Income	559.93	400.53	127.67	129.25	387.27	171.78
Earnings From Equity Investments	134.94	152.14	124.24	144.48	116.77	115.35
Currency Exchange Gain (Loss)	97.56	86.36	104.06	88.45	5.02	-10.25
Other Non Operating Income (Expenses)	875.62	878.52	536.42	486	51.17	49.44
EBT Excluding Unusual Items	25,371	22,750	16,372	18,613	16,270	14,816
Impairment of Goodwill	-	-	-38.52	-	-	-
Gain (Loss) on Sale of Investments	1,876	1,295	374.31	1,129	628.65	-224.41
Gain (Loss) on Sale of Assets	-9.6	4.8	16.65	-37.41	-30.45	109.54
Asset Writedown	-91.63	-91.63	-97.08	-57.63	-38.88	-207.66
Other Unusual Items	33.69	24.79	41.53	85.27	77.21	-123.14
Pretax Income	26,508	23,994	16,712	19,746	16,916	14,377
Income Tax Expense	5,125	4,576	3,616	5,216	3,986	3,816
Earnings From Continuing Operations	21,384	19,418	13,097	14,530	12,930	10,561
Minority Interest in Earnings	-233.95	-288.75	-278.17	-194.81	-276.07	-257.23
Net Income	21,150	19,129	12,819	14,335	12,654	10,304
Net Income to Common	21,150	19,129	12,819	14,335	12,654	10,304
Net Income Growth	35.79%	49.23%	-10.58%	13.28%	22.81%	78.11%
Shares Outstanding (Basic)	401	401	401	401	401	401
Shares Outstanding (Diluted)	401	401	401	401	401	401
Shares Change (YoY)	0.11%	0.14%	0.00%	-	-	-
EPS (Basic)	52.80	47.75	32.00	35.78	31.59	25.72
EPS (Diluted)	52.70	47.68	32.00	35.78	31.59	25.72
EPS Growth	35.63%	49.00%	-10.57%	13.27%	22.82%	78.12%
Free Cash Flow	19,993	18,371	10,243	4,549	8,318	8,442
Free Cash Flow Per Share	49.82	45.79	25.57	11.36	20.77	21.07
Dividend Per Share	-	-	-	-	-	3.100
Dividend Growth	-	-	-	-	-	-30.34%
Gross Margin	69.47%	67.87%	65.68%	68.03%	70.28%	67.27%
Operating Margin	21.80%	20.82%	18.15%	23.55%	25.59%	25.04%
Profit Margin	19.20%	18.51%	14.65%	18.42%	20.36%	17.55%
Free Cash Flow Margin	18.15%	17.78%	11.71%	5.85%	13.39%	14.38%
EBITDA	28,162	25,366	19,051	19,910	17,038	15,654
EBITDA Margin	25.56%	24.54%	21.77%	25.59%	27.42%	26.66%
D&A For EBITDA	4,143	3,848	3,168	1,588	1,135	948.47
EBIT	24,020	21,518	15,883	18,322	15,903	14,706
EBIT Margin	21.80%	20.82%	18.15%	23.55%	25.59%	25.04%
Effective Tax Rate	19.33%	19.07%	21.63%	26.42%	23.56%	26.54%
Revenue as Reported	113,903	106,156	88,780	79,776	63,854	59,757
Advertising Expenses	-	6,039	3,737	4,516	3,857	2,553

Source: S&P Capital IQ. Standard template. Financial Sources.